IMMX vs ARQT vs IQV vs CABA

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 23. 1x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Immix Biopharma, Inc. (IMMX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, IQVIA Holdings Inc.

is actually cheaper at 14. 2x.

Over the past 5 years, Immix Biopharma, Inc.

(IMMX) delivered a total return of +120. 7%, compared to -64. 8% for Cabaletta Bio, Inc. (CABA). Over 10 years, the gap is even starker: IQV returned +177. 5% versus CABA's -69. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IQVIA Holdings Inc.

(IQV) is the lower-risk stock at 1. 16β versus Cabaletta Bio, Inc. 's 2. 02β — meaning CABA is approximately 73% more volatile than IQV relative to the S&P 500. On balance sheet safety, Immix Biopharma, Inc. (IMMX) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -17. 1% for Immix Biopharma, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 2x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 108. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CABA: 442. 5% to $16. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IQVIA Holdings Inc.

(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), +177. 5% 10Y return). Cabaletta Bio, Inc. (CABA) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +177. 5%, CABA: -69. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMMX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; IQV is a mid-cap quality compounder stock; CABA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.